1.1Synthetic cannabinoid source
Chemical synthesis supplies purified cannabidiol without plant extraction. Chromatography measures cannabidiol content and related impurities before formulation for administration with the TRPV1 antagonist.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
Chemical synthesis supplies purified cannabidiol without plant extraction. Chromatography measures cannabidiol content and related impurities before formulation for administration with the TRPV1 antagonist.
A cream delivers capsaicin to intact skin, where it activates TRPV1 channels on cutaneous sensory nerve endings. Continued exposure reduces the responsiveness of those endings to subsequent stimulation.
A parenteral formulation delivers haloperidol during the acute episode. Haloperidol blocks D2 receptors involved in emetic signaling, and an electrocardiogram measures the corrected QT interval.
An intravenous isotonic crystalloid restores circulating volume depleted by repeated vomiting. Serum electrolyte measurements guide potassium and magnesium replacement.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A veterinary pharmacology assay exposes cultured canine sensory neurons to a marijuana-derived cannabinoid and a TRPV1 antagonist in the same well. A four-condition plate layout includes vehicle, cannabinoid alone, antagonist alone, and the pair. After exposure, a capsaicin challenge evokes a calcium signal, and fluorescence measurements quantify the response in each condition.
Chemically synthesized delta-9-tetrahydrocannabinol replaces the marijuana-derived cannabinoid in a paired-exposure assay. A liquid handler dispenses the synthetic compound and a TRPV1 antagonist from separate stock solutions into wells containing sensory neurons. The assay holds the carrier concentration constant across wells and records capsaicin-evoked calcium signals after exposure.
A perfusion chamber containing cultured sensory neurons connects to separate reservoirs for a marijuana-derived cannabinoid, a TRPV1 antagonist, and carrier solution. The antagonist enters the chamber 0, 5, or 15 minutes before the cannabinoid and remains present during cannabinoid exposure. A 60-second capsaicin pulse follows 10 minutes of joint exposure, and a camera records calcium fluorescence at 2 frames per second.
A clinical study uses an oral preparation containing a marijuana-derived cannabinoid and a separate topical preparation containing a TRPV1 antagonist. Staff apply the topical preparation over a measured 25-square-centimeter area of intact abdominal skin and record the application and oral administration times separately. Symptom assessments occur at baseline and at 30, 60, and 120 minutes after oral administration.
An electronic medication administration record links separate orders for a marijuana-derived cannabinoid and a TRPV1 antagonist under a shared study visit identifier. Barcode scanning matches each preparation to its order and records the lot number, route, and actual administration time. The record links those entries to symptom assessments from the same visit so reviewers can align each assessment with both administrations.
A liquid-handling robot dispenses a marijuana-derived cannabinoid and a TRPV1 antagonist across a concentration matrix in a plate containing cultured sensory neurons. An imaging system records baseline calcium fluorescence and captures the response after an automated capsaicin addition. Software calculates the peak fractional fluorescence change for each well and exports the result with both concentrations and the well identifier.
An oral soft capsule contains a measured quantity of plant-derived cannabidiol dissolved in a lipid vehicle. A separate immediate-release tablet contains a small-molecule TRPV1 antagonist, and the dosing protocol specifies administration of both units at the same visit.
A hard capsule contains two populations of granules, one carrying plant-derived cannabidiol and the other carrying a small-molecule TRPV1 antagonist. Chromatographic assays measure the amount of each active ingredient, and a dissolution test measures release from the finished capsule.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
In this study rats were first treated with vehicle (Oraplus/5% Tween 80) or a TRPV1 antagonist (Compound A; 3 mg/kg, p.o.). Following a 120 min period, separate groups of rats were then administered vehicle (Oraplus/5% Tween 80) or acetaminophen (300 mg/kg, p.o.).A · US 2006/0281718 A1 · ¶ 310
In this study rats were first treated with vehicle (Oraplus/5% Tween 80) or a TRPV1 antagonist (Compound A; 3 mg/kg, p.o.). Following a 120 min period, separate groups of rats were then administered vehicle (Oraplus/5% Tween 80) or acetaminophen (300 mg/kg, p.o.).B · US 2009/0312433 A1 · ¶ 319
An empty cell means only that no passage was reproduced there.
Since this effect may be considered an adverse event in humans, and may limit the amount of a VR1 antagonist that can be administered, preventing and/or reversing a temperature increase induced by treatment with a VR1 antagonist is important.A · US 2006/0281718 A1 · ¶ 5
This paradigm causes receptor activation induced desensitization of the primary sensory nerve—such reduction in sensory nerve activity in vivo makes subjects less sensitive to subsequent painful stimuli.A · US 2006/0281718 A1 · ¶ 4
Since this effect may be considered an adverse event in humans, and may limit the amount of a VR1 antagonist that can be administered, preventing and/or reversing a temperature increase induced by treatment with a VR1 antagonist is important.B · US 2009/0312433 A1 · ¶ 5
This paradigm causes receptor activation induced desensitization of the primary sensory nerve—such reduction in sensory nerve activity in vivo makes subjects less sensitive to subsequent painful stimuli.B · US 2009/0312433 A1 · ¶ 4
patent.fyi, US 2026/0355133 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355133/, SHA-256 b94f6cfb195bc727e455852eddd9aac3d457cbbf568e5e36f7aa1f1070b971a6